PMID- 35118454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 2752-5457 (Electronic)
IS  - 2752-5457 (Linking)
VI  - 17
IP  - 2
DP  - 2021 Nov
TI  - Changing the Concept: From the Traditional Glucose-centric to the New 
      Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.
PG  - 92-101
LID - 10.17925/EE.2021.17.2.92 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic disease with a constantly increasing 
      prevalence worldwide. It is well established that T2DM affects both the macro- 
      and microvasculature, and its presence is associated with a high risk of acute 
      and chronic cardiovascular events. Traditionally, the management of T2DM has been 
      mainly focused on the optimization of blood glucose levels with the use of 
      antidiabetic medications. During recent years, however, an impressive 
      accumulation of evidence has arisen from studies designed to explore the 
      plausible effects of new antidiabetic drugs on cardiovascular outcomes in 
      patients with diabetes. This review article aims to emphasize the findings of 
      these studies and to highlight the substantial role of the newer classes of 
      antidiabetic drugs in treating T2DM in a holistic, cardiorenal-metabolic 
      approach, thus shifting the paradigm from the traditional, simplistic, 
      glucose-lowering approach.
CI  - (c) Touch Medical Media 2021.
FAU - Chatzis, Dimitrios G
AU  - Chatzis DG
AD  - European University of Cyprus Medical School, Nicosia, Cyprus.
FAU - Kolokathis, Konstantinos
AU  - Kolokathis K
AD  - Department of Internal Medicine and Diabetes, Salamis Naval and Veterans 
      Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
FAU - Magounaki, Kalliopi
AU  - Magounaki K
AD  - European University of Cyprus Medical School, Nicosia, Cyprus.
FAU - Chatzidakis, Stefanos
AU  - Chatzidakis S
AD  - European University of Cyprus Medical School, Nicosia, Cyprus.
FAU - Avramidis, Konstantinos
AU  - Avramidis K
AD  - Department of Internal Medicine and Diabetes, Salamis Naval and Veterans 
      Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
FAU - Leopoulou, Marianna
AU  - Leopoulou M
AD  - Department of Cardiology, "Elpis" General Hospital, Athens, Greece.
FAU - Angelopoulos, Theodoros P
AU  - Angelopoulos TP
AD  - Iatriko Paleou Falirou Medical Center, Athens, Greece.
FAU - Doupis, John
AU  - Doupis J
AD  - Department of Internal Medicine and Diabetes, Salamis Naval and Veterans 
      Hospital, Salamis Naval Base, Salamis, Attiki, Greece.
AD  - Iatriko Paleou Falirou Medical Center, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211117
PL  - England
TA  - touchREV Endocrinol
JT  - TouchREVIEWS in endocrinology
JID - 101779126
PMC - PMC8676106
OTO - NOTNLM
OT  - Type 2 diabetes mellitus (T2DM)
OT  - cardiorenal-metabolic
OT  - glucose-lowering
OT  - treatment
COIS- Disclosures: Dimitrios G Chatzis, Konstantinos Kolokathis, Kalliopi Magounaki, 
      Stefanos Chatzidakis, Konstantinos Avramidis, Marianna Leopoulou, Theodoros P 
      Angelopoulos and John Doupis have no financial or non-financial relationships or 
      activities to declare in relation to this article.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/11/01
CRDT- 2022/02/04 05:54
PHST- 2020/07/02 00:00 [received]
PHST- 2021/06/29 00:00 [accepted]
PHST- 2022/02/04 05:54 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 10.17925/EE.2021.17.2.92 [doi]
PST - ppublish
SO  - touchREV Endocrinol. 2021 Nov;17(2):92-101. doi: 10.17925/EE.2021.17.2.92. Epub 
      2021 Nov 17.